Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDRA observational pemetrexed pharmacokinetics study with and without cisplatin hyperhydration
NL-OMON21433Active, not recruiting
- Sponsor
- Jeroen Bosch Hospital
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC) and mesothelioma, sponsored by Jeroen Bosch Hospital. Primary endpoint: Pemetrexed clearance difference with versus without hyperhydration. Started Apr 2018; status: active, not recruiting.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NL-OMON21433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21433.